Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2). Basically, the study aims to develop data for optimization of first-line therapy of T-ALL, either by modification of standard induction with Isatuximab or by establishing a post-induction therapy for eradication of MRD and thereby evaluates in parallel two different strategies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza białaczki limfoblastycznej T-komórkowej CD38 dodatniej, która wraca po leczeniu lub nie reaguje na leczenie
- •Wcześniejsze leczenie - co najmniej trzy cykle chemioterapii
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG 0-2)
- •Wystarczająca liczba płytek krwi (≥10 000/µL) i hemoglobiny (≥7,5 g/dL)
- •Prawidłowe funkcjonowanie wątroby i nerek
- •Kobiiety - negatywny test ciąży
- •Zgoda na uczestnictwo w badaniu i wykonanie wszystkich badań
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (15)
University Hospital Augsburg, II. Medizinischen Klinik, Hämatologie, internistische Onkologie und Hämostaseologie
Augsburg, Germany
Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt Hämatologie
Berlin, Germany
Gesundheit Nord Klinikverbund Bremen gGmbH, Klinikum Bremen-Mitte, Med. Klinik I
Bremen, Germany
Klinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I
Dresden, Germany
University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology
Düsseldorf, Germany
University Hospital Erlangen AöR, Department of Medicine 5
Erlangen, Germany
Goethe University Hospital Frankfurt, Department of Medicine, Hematology and Oncology
Frankfurt am Main, Germany
University Hospital Hamburg-Eppendorf, Department of Medicine II
Hamburg, Germany
University Hospital Heidelberg, Department V, Hematology, Oncology and Rheumatology
Heidelberg, Germany
University Hospital Schleswig-Holstein, Campus Kiel, Medical Department II
Kiel, Germany
University Hospital Leipzig; Klinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Bereich Hämatologie und Zelltherapie
Leipzig, Germany
University Hospital München-Großhadern, Medizinische Klinik und Poliklinik III
München, Germany
University Hospital Münster, Medizinische Klinik A / KMT-Zentrum
Münster, Germany
Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin - Onkologie und Hämatologie
Oldenburg, Germany
Robert-Bosch-Krankenhaus; Abteilung für Hämatologie, Onkologie und Palliativmedizin
Stuttgart, Germany
Trial contact
Nicola Goekbuget, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.